44 months extended follow up of checkmate 9ER trial for advanced RCC . Maximum benifit in poor risk category. No OS benifit in favorable risk category. Intresting to note subsequent therapies in those who completed 2 years of Nivolumab. ESMO - Eur. Oncology Tom Powles

It is a great initiative especially for cancer patients . I hope government implements uniform health care schemes across India in all states. At present, Maharashtra has MJPAY scheme and its coverage needs improvement ( newer drugs are not covered) and it is only for

Can u pronounce name of this latest approved drug by @usfda correctly? If yes , then you are true oncologist. ( if u know mechanism of action then u r genius 😀😀)
Try it out .
Nogapendekin alfa inbakicept -pmln .
IL-15 superagonist got approved for BCG unresponsive non

Er low Her2 negative breast cancer behave like TNBC. So should we give them IO like tnbc along with chemotherapy and endocrine therapy ? AnnalsSurgOncology Tessa Higgins Sara Tolaney Dr Sarah Sammons

WOW ‼️ WOW ‼️WOW ‼️

Will somebody please show this picture to these Columbia students
Who are telling us in mass chants “that they will create a human chain to push the Zionists out”

And cheering Hamas chants = cheering Nazi chants

#AntiSemitism
#IshallBearWitness
Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙

Government funding on research has increased in India over last decade . And it is maximum as compared to USA, China, Japan and Germany. Will business sector step up its investment in research? Taken from article in nature anand mahindra PMO India ICMR BJP

On this Good Deeds Day, we're highlighting the remarkable Dr. Manju Sengar, who heads the Medical Oncology Department of Tata Memorial Hospital in Mumbai, India🏥

#GoodDeedsDay #Oncology #CancerCare #TheMaxFoundation

As expected @usfda gave approval for adjuvant Alectinib for adjuvant NSCLC who are 4 CM or more in Size or node positive. Alectinib is approved at dose 600 Mg Twice a day along with food for 2 years or until disease recurrence or unacceptable toxicity.

KEYNOTE-564 (adj pembro renal) show OS benefit

BUT➡️Post-recurrence therapy is KEY in interpreting OS. Post-recurrence care in KEYNOTE-564 was clearly suboptimal.

Would the benefit be seen with optimal post-recurrence care : that's the Q❗️

Visual here: timotheeolivier-research.com/postrecurrence

Adjuvant Pembrolizumab shows OS benifit in RCC 👍👍. Keynote 564 .
1- 101 pts out of 210 pts who had recurrence ( less than 50 % ) on placebo arm got IO on recurrence ( assuming along with TKI as per current soc )
2 - Main benifit is for For M0 and
Intermediate to high

Ricardo Carvalho Dr Amol Akhade Santhosh Ambika Thank you for your interest. You can read and share, but not download, this paper via the following link: rdcu.be/dEZGX

Great initiative by @usfda. Project ASHA. Collaboration to increase clinical trial acess in India Geetika Srivastava MD MSPH bhawna sirohi Manju Sengar Pramesh CS

Useful flowchart for treatment algorithm for HCC in 2024. Published in NatureRevClinOncol

How to treat metastatic RCC and Urothelial carcinoma after progression on adjuvant IO ? Based upon available data. Very good slide for clinical decisions by Ursula Vogl ESMO - Eur. Oncology .

Useful tables for use of parp inhibitors in breast cancer in both early and advanced setting . And ongoing trials. Taken from article in JAMA Oncology by Stefania Morganti, MD and Carmine De Angelis .

Sanchi stupa . Bhopal . Madhya pradesh. India 🇮🇳. World heritage site. Foot prints of Lord Buddha. Ladder to heaven. From 3OO years BC.

Here are my concerns with today's FDA action
It's not surprising because FDA's primary client are the drug companies, and this will enrich them
youtu.be/-42d0z9faao

Dr Amol Akhade Here are my concerns
youtu.be/-42d0z9faao

ODAC approves MRD as surrogate end point for myeloma trials .
12 vs zero . Not a single vote against it . Is the corelation between MRD and OS good enough at trial level to get accelerated approvals ? Will this open gateway for MRD as end point for solid tumors? I hope not.

Fantastic discussions on our molecular mdt today !Good spin off - Collect real world data on pts with v high TMB/ ER+breast cancer. Thanks Dr. Shubham Pant for quick update on KRASG12C! Dr. Shona Nag dr nitesh rohatgi Aparna Raj Parikh Namrata (Neena) Vijayvergia MD Aparna Dhar Dr Amol Akhade Harsh Sheth